Ocugen Announces OCU400 Receives Orphan Drug Designations for Retinitis Pigmentosa and Leber Congenital Amaurosis
15 déc. 2022 17h15 HE
|
Ocugen
MALVERN, Pa., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen, Inc. to Ring the Nasdaq Stock Market Closing Bell
13 déc. 2022 08h00 HE
|
Ocugen
MALVERN, Pa., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis
07 déc. 2022 08h00 HE
|
Ocugen
Continued Positive Safety Data for OCU400 Established High Dose as the Maximum Tolerable Dose in Current OCU400 Clinical Trial MALVERN, Pa., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen...
Ocugen to Present at 3rd Annual Dry AMD Therapeutics Summit
28 nov. 2022 07h30 HE
|
Ocugen
MALVERN, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Ocugen Provides Business Update & Third Quarter 2022 Financial Results
08 nov. 2022 07h30 HE
|
Ocugen
Conference Call and Webcast Today at 8:30 a.m. ET Initiated dosing in the third and final cohort of U.S. Phase 1/2 OCU400 gene therapy clinical trialExpanded product pipeline with OCU500—Ocugen’s...
Ocugen to Host Conference Call on Tuesday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2022 Financial Results
27 oct. 2022 07h30 HE
|
Ocugen
MALVERN, Pa., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Ocugen to Host R&D Day in New York City on Tuesday, November 1, 2022
19 oct. 2022 07h30 HE
|
Ocugen
Highlighting Ocugen research and innovative technologies Featuring thought leaders in gene therapy and vaccines MALVERN, Pa., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the...
Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2
12 oct. 2022 17h37 HE
|
Ocugen
• No safety concerns noted in ongoing clinical trial• Study timeline remains on track MALVERN, Pa., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a...
Ocugen, Inc. to Present at Upcoming Vaccines, Cell & Gene Therapy Conferences
06 oct. 2022 08h00 HE
|
Ocugen
MALVERN, Pa., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Ocugen, Inc. to Present at Chardan’s 6th Annual Genetic Medicines Conference
29 sept. 2022 07h30 HE
|
Ocugen
MALVERN, Pa., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...